Exclusive Summary

• Innovative Mechanism: Recombinant L-IFN oncolytic adenovirus utilizes the 'Cancer Targeted Gene-Virotherapy (CTGVT)' strategy with dual regulation, offering broad-spectrum anti-cancer activity.
• Dual Regulatory Milestone: Successfully secured IND approvals from both the US FDA and China CDE, validating that its CMC and preclinical data meet stringent global regulatory standards.
• Strategic Asset: As a high-safety oncolytic virus with independent IP, it serves as an ideal candidate for combination therapies (e.g., with checkpoint inhibitors) to address cold tumors.

Asset Materials

Contact Us for Full Materials